Treatment of respiratory tract diseases and infections with ascorbic acid compositions

Inventors

Copeland, Dan • DURHAM, Carolyn • Richardson, Thomas E.

Assignees

Renovion Inc

Abstract

The application is directed to a method of inhibiting or reducing growth of clinical isolate bacteria comprising contacting the clinical isolate with a composition comprising glutathione, a glutathione derivative, a glutathione conjugate, a pharmaceutically-acceptable salt thereof, or any combination thereof.

Core Innovation

The disclosure describes compositions and methods for treating or reducing symptoms in a subject suffering from bronchiectasis in which clinical isolate bacteria chronic colonization infection occurs in the subject’s airway. The composition comprises glutathione, a glutathione conjugate, a pharmaceutically-acceptable salt thereof, or any combination thereof, and ascorbic acid, and the contacting occurs at a composition pH of about 6 to about 8.

The clinical isolate bacteria are Staphylococcus aureus, methicillin-resistant Staphylococcus aureus (MRSA), or both. The disclosure also describes inhibiting and reducing clinical isolate bacterial growth and biofilm, and administering compositions to subjects in airway-related contexts associated with bronchiectasis and chronic colonization infection.

The document further provides conjugate compounds as chemical structures with defined formulae, variable substituents, and linker groups, including pharmaceutically acceptable salts and solvates. The compounds may be enantiomerically enriched, and the disclosure includes composition-related considerations such as organic acids, including ascorbic acid, optional bicarbonate salt, and maintaining reduced glutathione and reduced ascorbic acid while minimizing oxidation.

Claims Coverage

The claim coverage centers on one independent method claim for bronchiectasis symptom treatment by airway administration of a glutathione composition plus ascorbic acid at about pH 6 to about 8, with dependent claims refining the isolate type, redox state, administration frequency, and antibiotic sensitization. In total, seven inventive features are identified.

The claims are directed to airway administration of a glutathione or glutathione conjugate composition together with ascorbic acid for treating or reducing bronchiectasis symptoms, with the composition contacting chronic airway-colonizing Staphylococcus aureus and/or MRSA at about pH 6 to about 8. Dependent refinements add antibiotic sensitization, specific pH and redox constraints, and twice-daily administration.

Stated Advantages

Documented Applications